m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00005)
| Regulator Name | RNA demethylase ALKBH5 (ALKBH5) | ||||
|---|---|---|---|---|---|
| Synonyms |
Alkylated DNA repair protein alkB homolog 5; Alpha-ketoglutarate-dependent dioxygenase alkB homolog 5; ABH5; OFOXD1
Click to Show/Hide
|
||||
| Gene Name | ALKBH5 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Apoptosis regulator Bcl-2 (BCL-2)
MCI-186 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [2] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [3] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [4] | ||
Oblimersen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [5] | ||
RG7601 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [6] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [7] | ||
APG-1252 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [8] | ||
APG-2575 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [9] | ||
AZD0466 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [10] | ||
Beclanorsen [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [11] | ||
Gossypol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [12] | ||
Obatoclax [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [13] | ||
PNT-2258 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [14] | ||
AI-850 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [15] | ||
BCL201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [16] | ||
BGB-11417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [17] | ||
BP1002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [18] | ||
LP-108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [19] | ||
Pc4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [20] | ||
VOB560 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [21] | ||
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [22] | ||
4,5-dibenzylbenzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [23] | ||
5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
Apogossypol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [25] | ||
BP-100-1.02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [26] | ||
modified HA14-1 compounds (cancer) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
QEDIIRNIARHLAQVGDSMDR [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [24] | ||
TW-37 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [27] | ||
WL-276 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [28] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [1], [29] | ||
Aurora kinase B (AURKB)
AT9283 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for AT9283. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AT9283 through regulating the expression of Aurora kinase B (AURKB). | [30], [31] | ||
ABT-348 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for ABT-348. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABT-348 through regulating the expression of Aurora kinase B (AURKB). | [30], [32] | ||
PHA-739358 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for PHA-739358. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PHA-739358 through regulating the expression of Aurora kinase B (AURKB). | [30], [31] | ||
| Aurora kinase B (AURKB) is a therapeutic target for PHA-739358. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PHA-739358 through regulating the expression of Aurora kinase B (AURKB). | [30], [33] | |||
VX-680 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for VX-680. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VX-680 through regulating the expression of Aurora kinase B (AURKB). | [30], [34] | ||
AMG 900 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for AMG 900. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMG 900 through regulating the expression of Aurora kinase B (AURKB). | [30], [35] | ||
AZD-1152-HQPA [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for AZD-1152-HQPA. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD-1152-HQPA through regulating the expression of Aurora kinase B (AURKB). | [30], [36] | ||
BI-811283 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for BI-811283. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BI-811283 through regulating the expression of Aurora kinase B (AURKB). | [30], [37] | ||
BI-831266 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for BI-831266. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BI-831266 through regulating the expression of Aurora kinase B (AURKB). | [30], [38] | ||
BI-847325 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for BI-847325. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BI-847325 through regulating the expression of Aurora kinase B (AURKB). | [30], [39] | ||
CYC116 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for CYC116. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CYC116 through regulating the expression of Aurora kinase B (AURKB). | [30], [40] | ||
GSK1070916 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for GSK1070916. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK1070916 through regulating the expression of Aurora kinase B (AURKB). | [30], [39] | ||
GSK1070916A [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for GSK1070916A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK1070916A through regulating the expression of Aurora kinase B (AURKB). | [30], [41] | ||
HPP-607 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for HPP-607. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HPP-607 through regulating the expression of Aurora kinase B (AURKB). | [30], [42] | ||
MK-5108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for MK-5108. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MK-5108 through regulating the expression of Aurora kinase B (AURKB). | [30], [43] | ||
R763 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for R763. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of R763 through regulating the expression of Aurora kinase B (AURKB). | [30], [44] | ||
SNS-314 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for SNS-314. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SNS-314 through regulating the expression of Aurora kinase B (AURKB). | [30], [45] | ||
TAK-901 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for TAK-901. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAK-901 through regulating the expression of Aurora kinase B (AURKB). | [30], [46] | ||
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine through regulating the expression of Aurora kinase B (AURKB). | [30], [47] | ||
6-bromoindirubin-3-oxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for 6-bromoindirubin-3-oxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6-bromoindirubin-3-oxime through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
7-bromoindirubin-3-oxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for 7-bromoindirubin-3-oxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 7-bromoindirubin-3-oxime through regulating the expression of Aurora kinase B (AURKB). | [30], [49] | ||
7-fluoroindirubin-3-acetoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for 7-fluoroindirubin-3-acetoxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 7-fluoroindirubin-3-acetoxime through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
CGP-57380 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for CGP-57380. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CGP-57380 through regulating the expression of Aurora kinase B (AURKB). | [30], [50] | ||
Deguelin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for Deguelin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Deguelin through regulating the expression of Aurora kinase B (AURKB). | [30], [42] | ||
HESPERADIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for HESPERADIN. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HESPERADIN through regulating the expression of Aurora kinase B (AURKB). | [30], [50] | ||
Indirubin-3'-monoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for Indirubin-3'-monoxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Indirubin-3'-monoxime through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
Indirubin-3-acetoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for Indirubin-3-acetoxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Indirubin-3-acetoxime through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
Indirubin-3-methoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for Indirubin-3-methoxime. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Indirubin-3-methoxime through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
ISIS 173813 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for ISIS 173813. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 173813 through regulating the expression of Aurora kinase B (AURKB). | [30], [48] | ||
ISIS 173831 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for ISIS 173831. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 173831 through regulating the expression of Aurora kinase B (AURKB). | [30], [51] | ||
ISIS 173840 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for ISIS 173840. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 173840 through regulating the expression of Aurora kinase B (AURKB). | [30], [51] | ||
ISIS 173848 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for ISIS 173848. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 173848 through regulating the expression of Aurora kinase B (AURKB). | [30], [51] | ||
quinazoline deriv. 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for quinazoline deriv. 1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of quinazoline deriv. 1 through regulating the expression of Aurora kinase B (AURKB). | [30], [52] | ||
SU 6656 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for SU 6656. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SU 6656 through regulating the expression of Aurora kinase B (AURKB). | [30], [53] | ||
PF-03814735 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aurora kinase B (AURKB) is a therapeutic target for PF-03814735. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-03814735 through regulating the expression of Aurora kinase B (AURKB). | [30], [54] | ||
Beta-catenin (CTNNB1)
Recombinant human endostatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). | [55], [56] | ||
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for C 82. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). | [55], [57] | ||
CEQ-508 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). | [55], [58] | ||
Bone morphogenetic protein 2 (BMP2)
DWP-431 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bone morphogenetic protein 2 (BMP2) is a therapeutic target for DWP-431. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DWP-431 through regulating the expression of Bone morphogenetic protein 2 (BMP2). | [59], [60] | ||
Calmodulin-dependent kinase II (CAMKK2)
STO609 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Calmodulin-dependent kinase II (CAMKK2) is a therapeutic target for STO609. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of STO609 through regulating the expression of Calmodulin-dependent kinase II (CAMKK2). | [61], [62] | ||
Cellular tumor antigen p53 (TP53)
Contusugene ladenovec [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Contusugene ladenovec. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Contusugene ladenovec through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [64] | ||
QPI-1002 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for QPI-1002. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of QPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [65] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [66] | ||
Ad-p53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Ad-p53. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ad-p53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [67] | ||
ALT-801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ALT-801. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ALT-801 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [68] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APG-115. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of APG-115 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [69] | ||
APR-246 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APR-246. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of APR-246 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [70] | ||
Cenersen [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Cenersen. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cenersen through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [71] | ||
INGN-225 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-225. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INGN-225 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [63] | ||
ISA-P53-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ISA-P53-01. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISA-P53-01 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [72] | ||
Kevetrin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Kevetrin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Kevetrin through regulating the expression of Cellular tumor antigen p53 (TP53). | [13], [63] | ||
OPI-1002 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for OPI-1002. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [73] | ||
SGT-53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SGT-53. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SGT-53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [63] | ||
CGM097 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for CGM097. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CGM097 through regulating the expression of Cellular tumor antigen p53 (TP53). | [15], [63] | ||
COTI-2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for COTI-2. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of COTI-2 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [74] | ||
Dendritic cell vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Dendritic cell vaccine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Dendritic cell vaccine through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [75] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for HDM201. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HDM201 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [76] | ||
ONYX-015 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ONYX-015. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ONYX-015 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [77] | ||
SAR-405838 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SAR-405838. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SAR-405838 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [64] | ||
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [78] | ||
AHL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for AHL. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AHL through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [79] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NU-8231. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NU-8231 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [80] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NUTLIN-3. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NUTLIN-3 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [81] | ||
INGN-234 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-234. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INGN-234 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [82] | ||
Pifithrin-alpha [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Pifithrin-alpha. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pifithrin-alpha through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [83] | ||
TAR-1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for TAR-1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAR-1 through regulating the expression of Cellular tumor antigen p53 (TP53). | [63], [84] | ||
Deubiquitinating enzyme 1 (USP1)
ML323 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Deubiquitinating enzyme 1 (USP1) is a therapeutic target for ML323. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ML323 through regulating the expression of Deubiquitinating enzyme 1 (USP1). | [85], [86] | ||
DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
Curcumin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for Curcumin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Curcumin through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [88] | ||
(L-)-S-adenosyl-L-homocysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for (L-)-S-adenosyl-L-homocysteine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (L-)-S-adenosyl-L-homocysteine through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-106084 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-106084. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-106084 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-137546 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-137546. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-137546 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-138419 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-138419. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-138419 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-154957 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-154957. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-154957 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-158324 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-158324. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-158324 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-319745 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-319745. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-319745 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-345763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-345763. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-345763 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-348926 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-348926. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-348926 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-401077 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-401077. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-401077 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-54162 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-54162. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-54162 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-56071 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-56071. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-56071 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-57893 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-57893. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-57893 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-622444 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-622444. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-622444 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
NSC-622445 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-622445. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-622445 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [90] | ||
NSC-623548 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for NSC-623548. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-623548 through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [89] | ||
S-tubercidinylhomocysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for S-tubercidinylhomocysteine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of S-tubercidinylhomocysteine through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). | [87], [91] | ||
Ephrin type-B receptor 2 (EPHB2)
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [92], [93] | ||
SEphB4-HSA [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SEphB4-HSA. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SEphB4-HSA through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [92], [94] | ||
KO-947 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for KO-947. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KO-947 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [92] | ||
MK-8353 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for MK-8353. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MK-8353 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [92] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [92], [95] | ||
SNEWIQPRLPQH [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SNEWIQPRLPQH. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SNEWIQPRLPQH through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [15], [92] | ||
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [96] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [97] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [98] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [99] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [100] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [101] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [102] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [103] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [104] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [102] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [105] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [107] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [108] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [109] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [110] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [111] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [112] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [113] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [114] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [115] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [7] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [97] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [96] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [116] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [117] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [118] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [119] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [114] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [120] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [121] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [122] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [123] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [124] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [125] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [126] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [127] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [128] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [129] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [130] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [131] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [132] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [122] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [133] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [134] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [135] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [136] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [137] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [138] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [64] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [139] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [140] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [141] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [142] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [143] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [144] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [145] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [146] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [147] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [148] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [15] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [149] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [122] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [150] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [151] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [122] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [152] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [154] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [155] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [156] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [157] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [158] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [159] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [160] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [161] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [162] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [163] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [164] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [165] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [154] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [166] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [167] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [169] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [170] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [171] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [172] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [161] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [161] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [173] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [153] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [174] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [175] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [165] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [166] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [176] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [167] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [177] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [178] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [179] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [180] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [161] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [181] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [158] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [182] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [168] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [183] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [184] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [185] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [186] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [174] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [182] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [156] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [154] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [184] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [158] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [154] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [187] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [155] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [155] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [154] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [186] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [131] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [188] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [189] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [181] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [158] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [190] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [172] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [106] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [191] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [31] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [192] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [131] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [193] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [194] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [195] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [196] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [197] | ||
Forkhead box protein M1 (FOXM1)
(D-Arg)(9)-p19(ARF) 26-44 peptide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein M1 (FOXM1) is a therapeutic target for (D-Arg)(9)-p19(ARF) 26-44 peptide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (D-Arg)(9)-p19(ARF) 26-44 peptide through regulating the expression of Forkhead box protein M1 (FOXM1). | [198], [199] | ||
Frizzled-10 (FZD10)
OTSA-101-DTPA-90Y [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Frizzled-10 (FZD10) is a therapeutic target for OTSA-101-DTPA-90Y. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OTSA-101-DTPA-90Y through regulating the expression of Frizzled-10 (FZD10). | [64], [200] | ||
High mobility group protein B1 (HMGB1)
2-Sulfhydryl-Ethanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | High mobility group protein B1 (HMGB1) is a therapeutic target for 2-Sulfhydryl-Ethanol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-Sulfhydryl-Ethanol through regulating the expression of High mobility group protein B1 (HMGB1). | [201], [202] | ||
Hypoxia-inducible factor 1 alpha (HIF-1A)
HIF-1alpha [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for HIF-1alpha. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HIF-1alpha through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [204] | ||
IT-101 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for IT-101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IT-101 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [205] | ||
2-Methoxyestradiol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for 2-Methoxyestradiol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-Methoxyestradiol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [206] | ||
PT2385 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PT2385. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PT2385 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [207] | ||
ENMD-1198 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ENMD-1198. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ENMD-1198 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [208] | ||
EZN-2968 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for EZN-2968. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of EZN-2968 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [209] | ||
PX-478 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PX-478. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PX-478 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [210] | ||
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [15], [203] | ||
ISIS 175510 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 175510. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 175510 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298697 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298697. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298697 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298699. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298699 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298700 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298700. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298700 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298701 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298701. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298701 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298702 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298702. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298702 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298711 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298711. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298711 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298712 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298712. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298712 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298743 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298743. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298743 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298744 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298744. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298744 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298745 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298745. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298745 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [211] | ||
ISIS 298746 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298746. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 298746 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [203], [212] | ||
Insulin-like growth factor I receptor (IGF1R)
Mecasermin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Mecasermin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Mecasermin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [214] | ||
Somatomedin-1 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Somatomedin-1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Somatomedin-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [15], [213] | ||
Teprotumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Teprotumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Teprotumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [215] | ||
Rinfabate [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Rinfabate. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Rinfabate through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [216] | ||
AMG 479 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMG 479. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMG 479 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [7], [213] | ||
AXL-1717 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AXL-1717. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AXL-1717 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [125], [213] | ||
Cixutumumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cixutumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cixutumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [217] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for MM-141. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MM-141 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [218] | ||
R1507 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for R1507. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of R1507 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [219] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for TT-100. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TT-100 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [220] | ||
VPI-2690B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for VPI-2690B. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VPI-2690B through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [221] | ||
AEW-541 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AEW-541. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AEW-541 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [222] | ||
BIIB 022 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BIIB 022. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BIIB 022 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [223] | ||
Cyclolignan picropodophyllin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cyclolignan picropodophyllin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cyclolignan picropodophyllin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [31], [213] | ||
FPI-1434 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for FPI-1434. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FPI-1434 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [224] | ||
HF-0299 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for HF-0299. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HF-0299 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [225] | ||
RG-7010 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for RG-7010. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG-7010 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [226] | ||
ATL-1101 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for ATL-1101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ATL-1101 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [89], [213] | ||
BMS-695735 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS-695735. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-695735 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [152], [213] | ||
4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [227] | ||
4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [228] | ||
AG 1024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AG 1024. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG 1024 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [229] | ||
Alpha-D-Mannose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Alpha-D-Mannose. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Alpha-D-Mannose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [230] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [230] | ||
AZD3463 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AZD3463. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD3463 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [231] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [227] | ||
Fucose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Fucose. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Fucose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [4], [213] | ||
GSK-1838705A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK-1838705A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK-1838705A through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [232] | ||
GSK1511931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK1511931. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK1511931 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [233] | ||
JB-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for JB-1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of JB-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [234] | ||
NVP-ADW742 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for NVP-ADW742. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NVP-ADW742 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [4], [213] | ||
PQ401 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for PQ401. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PQ401 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [235] | ||
AVE-1642 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AVE-1642. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AVE-1642 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [236] | ||
Figitumumab [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Figitumumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Figitumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [64], [213] | ||
KW-2450 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for KW-2450. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KW-2450 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [213], [237] | ||
Interferon-beta (IFNB1)
Interferon beta-1a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta-1a. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Interferon beta-1a through regulating the expression of Interferon-beta (IFNB1). | [238], [239] | ||
PEGylated IFN beta 1-a [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PEGylated IFN beta 1-a. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PEGylated IFN beta 1-a through regulating the expression of Interferon-beta (IFNB1). | [238], [240] | ||
PLEGRIDY [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PLEGRIDY. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PLEGRIDY through regulating the expression of Interferon-beta (IFNB1). | [238], [241] | ||
Biferonex [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Biferonex. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Biferonex through regulating the expression of Interferon-beta (IFNB1). | [238], [242] | ||
FP-1201 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). | [238], [243] | ||
NU-100 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for NU-100. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NU-100 through regulating the expression of Interferon-beta (IFNB1). | [238], [244] | ||
AZ-01, PEGylated interferon-beta [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for AZ-01, PEGylated interferon-beta. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZ-01, PEGylated interferon-beta through regulating the expression of Interferon-beta (IFNB1). | [64], [238] | ||
Interferon beta 1a [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Interferon beta 1a. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Interferon beta 1a through regulating the expression of Interferon-beta (IFNB1). | [238], [245] | ||
PF-06823859 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for PF-06823859. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-06823859 through regulating the expression of Interferon-beta (IFNB1). | [238], [245] | ||
ARX-424 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for ARX-424. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ARX-424 through regulating the expression of Interferon-beta (IFNB1). | [238], [246] | ||
Gene therapy, IFN-b [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Gene therapy, IFN-b. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Gene therapy, IFN-b through regulating the expression of Interferon-beta (IFNB1). | [238], [247] | ||
TV-1390 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for TV-1390. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TV-1390 through regulating the expression of Interferon-beta (IFNB1). | [238], [245] | ||
Maxy-10 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-beta (IFNB1) is a therapeutic target for Maxy-10. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Maxy-10 through regulating the expression of Interferon-beta (IFNB1). | [238], [248] | ||
Janus kinase 2 (JAK-2)
Baricitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Baricitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Baricitinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [250] | ||
Fedratinib [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [251] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [269] | |||
Ruxolitinib [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [252] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2). | [58], [249] | |||
CYT-387 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CYT-387. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CYT-387 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [253] | ||
ITF2357 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for ITF2357. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ITF2357 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [254] | ||
Pacritinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Pacritinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pacritinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [255] | ||
XL019 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for XL019. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of XL019 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [256] | ||
AZD1480 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AZD1480. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD1480 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [257] | ||
BMS-911543 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for BMS-911543. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-911543 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [258] | ||
Cerdulatinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Cerdulatinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cerdulatinib through regulating the expression of Janus kinase 2 (JAK-2). | [249], [259] | ||
CTP-543 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [260] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [256] | |||
INCB039110 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for INCB039110. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INCB039110 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [261] | ||
LY2784544 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for LY2784544. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY2784544 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [262] | ||
NS-018 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for NS-018. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NS-018 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [260] | ||
AC430 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AC430. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AC430 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [263] | ||
Peginterferon beta [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Peginterferon beta. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Peginterferon beta through regulating the expression of Janus kinase 2 (JAK-2). | [249], [252] | ||
SB-1578 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for SB-1578. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SB-1578 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [264] | ||
1,2,3,4,5,6-hexabromocyclohexane [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for 1,2,3,4,5,6-hexabromocyclohexane. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 1,2,3,4,5,6-hexabromocyclohexane through regulating the expression of Janus kinase 2 (JAK-2). | [249], [265] | ||
5-phenyl-1H-indazol-3-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for 5-phenyl-1H-indazol-3-amine. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 5-phenyl-1H-indazol-3-amine through regulating the expression of Janus kinase 2 (JAK-2). | [249], [266] | ||
AMG-JAK2-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AMG-JAK2-01. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AMG-JAK2-01 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [260] | ||
Atropisomer 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Atropisomer 1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Atropisomer 1 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [267] | ||
AZ960 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AZ960. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZ960 through regulating the expression of Janus kinase 2 (JAK-2). | [70], [249] | ||
BVB-808 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for BVB-808. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BVB-808 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [268] | ||
CMP-6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CMP-6. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CMP-6 through regulating the expression of Janus kinase 2 (JAK-2). | [190], [249] | ||
K-454 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for K-454. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of K-454 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [270] | ||
NSC-1771 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for NSC-1771. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NSC-1771 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [271] | ||
ON-044580 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for ON-044580. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ON-044580 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [260] | ||
SGI-1252 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for SGI-1252. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SGI-1252 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [272] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for WHI-P154. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WHI-P154 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [273] | ||
AG490 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AG490. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AG490 through regulating the expression of Janus kinase 2 (JAK-2). | [249], [252] | ||
Kruppel like factor 4 (KLF4)
APTO-253 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Kruppel like factor 4 (KLF4) is a therapeutic target for APTO-253. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of APTO-253 through regulating the expression of Kruppel like factor 4 (KLF4). | [73], [274] | ||
MADH6 messenger RNA (MADH6 mRNA)
ISIS 101952 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101952. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101952 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101960 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101960. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101960 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101983 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101983. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101983 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101984 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101984. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101984 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101985 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101985. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101985 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101986 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101986. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101986 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101987 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101987. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101987 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101995 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101995. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101995 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101996 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101996. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101996 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101997 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101997. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101997 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [276] | ||
ISIS 101998 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101998. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101998 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). | [275], [277] | ||
Mothers against decapentaplegic homolog 3 (SMAD3)
FLUORESCEIN [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [275], [278] | ||
SIS-3 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for SIS-3. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SIS-3 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [267], [275] | ||
ELLAGIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [267], [275] | ||
GNF-PF-2272 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for GNF-PF-2272. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GNF-PF-2272 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [275], [279] | ||
PI3-kinase alpha (PIK3CA)
Alpelisib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Alpelisib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Alpelisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [107] | ||
BAY 80-6946 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BAY 80-6946. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BAY 80-6946 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [204] | ||
Buparlisib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Buparlisib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [280] | ||
GDC-0032 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for GDC-0032. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GDC-0032 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [281] | ||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for LY3023414. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY3023414 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [282] | ||
MLN1117 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for MLN1117. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MLN1117 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [283] | ||
PA-799 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PA-799. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [284] | ||
BLY719 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BLY719. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BLY719 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [64] | ||
HHCYH33 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for HHCYH33. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of HHCYH33 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [285] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [286] | ||
ETP-46321 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for ETP-46321. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ETP-46321 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1], [287] | ||
Programmed cell death 1 ligand 1 (PD-L1)
Atezolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Atezolizumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Atezolizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [289] | ||
Avelumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Avelumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Avelumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [241], [288] | ||
Bavencio [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bavencio. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bavencio through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [290] | ||
Durvalumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Durvalumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Durvalumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
RG-7446 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG-7446. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG-7446 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [292] | ||
CS1001 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CS1001. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CS1001 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [293] | ||
KN046 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN046. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KN046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [294] | ||
MEDI4736 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MEDI4736. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MEDI4736 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [295] | ||
MPDL-3280A [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MPDL-3280A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MPDL-3280A through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [296] | ||
BGB-A333 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BGB-A333. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BGB-A333 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [297] | ||
Bintrafusp alfa [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bintrafusp alfa. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bintrafusp alfa through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [298] | ||
CX-072 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CX-072. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CX-072 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [299] | ||
GS-4224 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GS-4224. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GS-4224 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [300] | ||
INCB86550 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INCB86550. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INCB86550 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [301] | ||
KN035 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN035. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KN035 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [302] | ||
M7824 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for M7824. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of M7824 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [122], [288] | ||
NM21-1480 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for NM21-1480. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NM21-1480 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
Pidilizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [15], [288] | ||
ALPN-202 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for ALPN-202. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ALPN-202 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [303] | ||
Anti-PD-L1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Anti-PD-L1 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [304] | ||
Anti-PD-L1 CSR T cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1 CSR T cells. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Anti-PD-L1 CSR T cells through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [15], [288] | ||
BMS-986189 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BMS-986189. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-986189 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
CA-170 [Phase 1]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [122], [288] | ||
| Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [305] | |||
Cosibelimab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Cosibelimab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cosibelimab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [306] | ||
FAZ053 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FAZ053. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FAZ053 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
FS118 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FS118. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of FS118 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [307] | ||
GEN1046 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GEN1046. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GEN1046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [308] | ||
IBI318 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for IBI318. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IBI318 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [309] | ||
INBRX-105 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INBRX-105. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INBRX-105 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [310] | ||
KD033 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KD033. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KD033 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [311] | ||
LY3300054 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3300054. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY3300054 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [15], [288] | ||
LY3415244 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [312] | ||
MCLA-145 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MCLA-145. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MCLA-145 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [313] | ||
MSB2311 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MSB2311. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MSB2311 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
PD-L1 t-haNK [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for PD-L1 t-haNK. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PD-L1 t-haNK through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [314] | ||
RG6084 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG6084. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RG6084 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [122], [288] | ||
TAK-252 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for TAK-252. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAK-252 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [315] | ||
CA-327 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-327. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CA-327 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [288], [291] | ||
Protein phosphatase 1A (PPM1A)
VP-102 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). | [61], [316] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [318] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [319] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [31], [317] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [320] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [145], [317] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [322] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [323] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [324] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [323] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [323] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [325] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [230], [317] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [233], [317] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [326] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [323] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [327] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [328] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [326] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [329] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [330] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [323] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [331] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [332] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [330] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [317], [321] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [15], [317] | ||
Signal transducer and activator of transcription 3 (STAT3)
Acitretin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Acitretin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Acitretin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [334] | ||
Napabucasin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Napabucasin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Napabucasin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [335] | ||
Atiprimod [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Atiprimod. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Atiprimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [336] | ||
GLG-801 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GLG-801. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GLG-801 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [337] | ||
Golotimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Golotimod. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Golotimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [333] | ||
IMX-110 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for IMX-110. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IMX-110 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [333] | ||
ISIS-STAT3 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS-STAT3. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS-STAT3 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
NT219 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for NT219. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NT219 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [339] | ||
OPB-31121 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-31121. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OPB-31121 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [333] | ||
WP-1066 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP-1066. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WP-1066 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [333] | ||
C188-9 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for C188-9. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C188-9 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [340] | ||
DSP-0337 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for DSP-0337. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DSP-0337 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [4], [333] | ||
OPB-111077 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-111077. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OPB-111077 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [341] | ||
OPB-51602 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-51602. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OPB-51602 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [342] | ||
TAK-114 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for TAK-114. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAK-114 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [343] | ||
WP1220 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP1220. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of WP1220 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [344] | ||
GNF-PF-1399 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GNF-PF-1399. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GNF-PF-1399 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [345] | ||
ISIS 113176 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113176. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 113176 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
ISIS 113187 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113187. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 113187 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
ISIS 113209 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113209. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 113209 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
ISIS 113210 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113210. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 113210 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [15], [333] | ||
ISIS 17148 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
ISIS 17152 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17152. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 17152 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [333], [338] | ||
Sphingosine kinase 1 (SPHK1)
Phenoxodiol [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for Phenoxodiol. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Phenoxodiol through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [347] | ||
GSK618334 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for GSK618334. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK618334 through regulating the expression of Sphingosine kinase 1 (SPHK1). | [64], [346] | ||
YP-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for YP-005. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of YP-005 through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [348] | ||
PF-543 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for PF-543. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-543 through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [349] | ||
SK1-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for SK1-I. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SK1-I through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [350] | ||
VPC-94075 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for VPC-94075. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VPC-94075 through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [351] | ||
B-5354a [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for B-5354a. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of B-5354a through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [352] | ||
F-12509A [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sphingosine kinase 1 (SPHK1) is a therapeutic target for F-12509A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of F-12509A through regulating the expression of Sphingosine kinase 1 (SPHK1). | [346], [353] | ||
SRSF protein kinase 1 (SRPK1)
SPHINX31 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | SRSF protein kinase 1 (SRPK1) is a therapeutic target for SPHINX31. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SPHINX31 through regulating the expression of SRSF protein kinase 1 (SRPK1). | [354], [355] | ||
Stimulator of interferon genes protein (TMEM173)
ADU- S100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for ADU- S100. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ADU- S100 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [356] | ||
ADU-S100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for ADU-S100. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ADU-S100 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [357] | ||
IMSA101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for IMSA101. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of IMSA101 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [15], [201] | ||
MK-1454 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for MK-1454. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MK-1454 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [358] | ||
BMS-986301 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for BMS-986301. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS-986301 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [359] | ||
E7766 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for E7766. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of E7766 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [360] | ||
GSK3745417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for GSK3745417. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GSK3745417 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [361] | ||
MK-2118 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for MK-2118. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MK-2118 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [362] | ||
SB 11285 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for SB 11285. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SB 11285 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [363] | ||
SNX281 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for SNX281. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SNX281 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [364] | ||
SYNB1891 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for SYNB1891. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of SYNB1891 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [365] | ||
TAK-676 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for TAK-676. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TAK-676 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [366] | ||
C-176 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for C-176. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C-176 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [367] | ||
C-178 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stimulator of interferon genes protein (TMEM173) is a therapeutic target for C-178. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C-178 through regulating the expression of Stimulator of interferon genes protein (TMEM173). | [201], [368] | ||
Stress-activated protein kinase JNK1 (JNK1)
NKP-1339 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NKP-1339. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NKP-1339 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [369] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for COR-D. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of COR-D through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [370] | ||
2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [323] | ||
2-(2-butoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-butoxypyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-butoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
2-(2-phenoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
2-(2-propoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-propoxypyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-propoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [372] | ||
Aminopyridine deriv. 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Aminopyridine deriv. 2. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Aminopyridine deriv. 2 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [373] | ||
AS-601245 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for AS-601245. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AS-601245 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [371] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Bisindolylmaleimide-I. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [50], [92] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for CI-1040. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CI-1040 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [370] | ||
JNK-IN-8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for JNK-IN-8. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of JNK-IN-8 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [230] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for KN-62. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KN-62 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [327] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for KT-5720. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of KT-5720 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [374] | ||
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [375] | ||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [375] | ||
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [323] | ||
N-(6-ethoxypyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(6-ethoxypyridin-2-yl)acetamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(6-ethoxypyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [375] | ||
NM-PP1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NM-PP1. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NM-PP1 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [323] | ||
Phylomers [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Phylomers. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Phylomers through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [375] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for RO-316233. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RO-316233 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [323] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Ro31-8220. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ro31-8220 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [50], [92] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for STAUROSPORINONE. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [92], [323] | ||
TGF-beta receptor type II (TGFBR2)
TGF-BR2 mab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | TGF-beta receptor type II (TGFBR2) is a therapeutic target for TGF-BR2 mab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TGF-BR2 mab through regulating the expression of TGF-beta receptor type II (TGFBR2). | [275], [376] | ||
LY2109761 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | TGF-beta receptor type II (TGFBR2) is a therapeutic target for LY2109761. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LY2109761 through regulating the expression of TGF-beta receptor type II (TGFBR2). | [275], [377] | ||
Transferrin receptor protein 1 (TFRC)
ABBV-CX-2029 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transferrin receptor protein 1 (TFRC) is a therapeutic target for ABBV-CX-2029. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ABBV-CX-2029 through regulating the expression of Transferrin receptor protein 1 (TFRC). | [378], [379] | ||
Tyrosine-protein kinase UFO (AXL)
Gilteritinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Gilteritinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Gilteritinib through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [381] | ||
Bemcentinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Bemcentinib. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Bemcentinib through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [382] | ||
BGB-324 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BGB-324. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BGB-324 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [383] | ||
BI-505 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BI-505. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BI-505 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [15], [380] | ||
Enapotamab vedotin [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Enapotamab vedotin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Enapotamab vedotin through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [384] | ||
MGCD265 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for MGCD265. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of MGCD265 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [145], [380] | ||
ONO-7475 [Phase 1/2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for ONO-7475. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [385] | ||
| Tyrosine-protein kinase UFO (AXL) is a therapeutic target for ONO-7475. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [15], [380] | |||
TP-0903 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for TP-0903. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of TP-0903 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [386] | ||
AVB-S6-500 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for AVB-S6-500. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of AVB-S6-500 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [387] | ||
BPI-9016 M [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BPI-9016 M. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BPI-9016 M through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [15], [380] | ||
DS-1205 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for DS-1205. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DS-1205 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [15], [380] | ||
INCB81776 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for INCB81776. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of INCB81776 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [388] | ||
PF-07265807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for PF-07265807. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-07265807 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [389] | ||
RXDX-106 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for RXDX-106. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of RXDX-106 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [390] | ||
Cu-anti-hAXL [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Cu-anti-hAXL. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Cu-anti-hAXL through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [15], [380] | ||
DP-3975 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for DP-3975. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of DP-3975 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [391] | ||
GL21.T [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for GL21.T. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of GL21.T through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [391] | ||
YW327.6S2 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for YW327.6S2. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of YW327.6S2 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [392] | ||
LDC1267 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for LDC1267. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [380], [391] | ||
References